American Journal of Clinical Dermatology最新文献

{"title":"Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis.","authors":"Amalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, Raj Chovatiya, Mia-Louise Nielsen, Farzad Alinaghi, Simon F Thomsen, Christian Vestergaard, Andreas Wollenberg, Alexander Egeberg, Jacob P Thyssen, Nikolai Loft","doi":"10.1007/s40257-026-01025-2","DOIUrl":"https://doi.org/10.1007/s40257-026-01025-2","url":null,"abstract":"","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.8,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE.","authors":"Gil Yosipovitch, Melinda J Gooderham, Sarina B Elmariah, Gianluca Bonfanti, Roger A Edwards, Stamatios Gregoriou, Pinaki Biswas, Daniela E Myers, Justine Alderfer, Erman Güler, Christopher Koulias","doi":"10.1007/s40257-026-01030-5","DOIUrl":"https://doi.org/10.1007/s40257-026-01030-5","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis is a chronic immune-inflammatory skin disease that significantly impairs quality of life, with itch representing a key, but not exclusive, contributor to this burden.</p><p><strong>Objective: </strong>We aimed to evaluate itch relief and quality-of-life improvements with abrocitinib or dupilumab for 16 weeks alongside topical therapy in patients with moderate-to-severe atopic dermatitis.</p><p><strong>Methods: </strong>This post hoc analysis included pooled data from patients who received abrocitinib (200 mg/day) or dupilumab (300 mg/every 2 weeks) in phase III JADE COMPARE and JADE DARE. Assessments included proportions of patients achieving a ≥ 4-point improvement from baseline in Peak Pruritus Numerical Rating Scale (PP-NRS4), itch-free state (PP-NRS 0/1) by baseline itch severity, and proportions of patients with residual itch achieving Dermatology Life Quality Index score of 0/1 (DLQI 0/1), total Patient-Oriented Eczema Measure (POEM) score ≤ 2, SCORing Atopic Dermatitis (SCORAD) sleep loss visual analog scale score of 0/1 (SCORAD sleep loss visual analog scale 0/1), and POEM sleep item score of 0 (POEM sleep 0).</p><p><strong>Results: </strong>Among 1196 patients (abrocitinib, n = 588; dupilumab, n = 608), those with greater baseline itch severity experienced greater atopic dermatitis severity and worse quality of life than patients with less severe itch. At week 16, numerically more patients achieved PP-NRS4 (67% vs 63%) and PP-NRS 0/1 (36% vs 27%) with abrocitinib versus dupilumab, respectively, regardless of baseline itch severity, although 95% confidence intervals overlapped for both measures. Median time to achieve PP-NRS4 (11 vs 29 days) and PP-NRS 0/1 (57 vs 139 days) was shorter with abrocitinib versus dupilumab, respectively. Numerically greater proportions of patients achieving PP-NRS 0/1 also achieved DLQI 0/1, POEM ≤ 2, SCORAD sleep loss visual analog scale 0/1, or POEM sleep 0 than patients with residual itch (PP-NRS ≥ 2).</p><p><strong>Conclusions: </strong>In this post hoc pooled analysis of the JADE COMPARE and JADE DARE trials, the proportion of patients with moderate-to-severe atopic dermatitis achieving clinically meaningful itch responses, including an itch-free state, was generally higher with abrocitinib compared with dupilumab. Median time to achievement of both PP-NRS4 and an itch-free state was shorter with abrocitinib than with dupilumab. Patients who achieved an itch-free state experienced greater improvements in quality of life and sleep compared with patients with residual itch.</p><p><strong>Clinical trial registration: </strong>JADE COMPARE (NCT03720470; registration date: 2018/10/24); JADE DARE (NCT04345367; registration date: 2020/04/10).</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.8,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment with Lebrikizumab or Tralokinumab for Atopic Dermatitis: A 60-Week Retrospective Comparative Study.","authors":"Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei-Ichiro Motegi, Naoko Kanda","doi":"10.1007/s40257-026-01036-z","DOIUrl":"https://doi.org/10.1007/s40257-026-01036-z","url":null,"abstract":"","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.8,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients.","authors":"Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei-Ichiro Motegi, Naoko Kanda","doi":"10.1007/s40257-026-01033-2","DOIUrl":"https://doi.org/10.1007/s40257-026-01033-2","url":null,"abstract":"<p><strong>Background: </strong>An anti-interleukin (IL)‑13 antibody, lebrikizumab, has shown efficacy in the treatment of atopic dermatitis (AD). However, real‑world data on 1‑year transition of clinical and laboratory indices are limited.</p><p><strong>Objectives: </strong>To evaluate the 48‑week transition of clinical and laboratory indices during lebrikizumab treatment in Japanese patients with moderate‑to‑severe AD, stratified by the presence or absence of prior systemic therapy.</p><p><strong>Methods: </strong>We conducted a two‑center prospective study of 187 Japanese patients with AD treated with lebrikizumab. Clinical and laboratory indices were assessed until week 48 in systemic therapy-naive and -experienced patients.</p><p><strong>Results: </strong>Lebrikizumab reduced total and anatomical site-specific eczema area and severity index (EASI) and the peak pruritus numerical rating scale (PP‑NRS) throughout the 48 weeks. The magnitude of decreasing head and neck EASI was slightly lower in systemic therapy-experienced patients. Week 48 achievement rates of EASI 75, EASI 90, and PP‑NRS 4 were 84%, 61.8%, and 79.3% in systemic therapy-naive patients, and 68.8%, 41.7%, and 75% in systemic therapy-experienced patients, respectively. Lebrikizumab decreased immunoglobulin E, thymus and activation-regulated chemokine, and lactate dehydrogenase throughout 48 weeks.</p><p><strong>Conclusion: </strong>In a 48‑week real‑world practice, lebrikizumab showed favorable effectiveness for AD, with higher responses in systemic therapy-naive patients compared with systemic therapy-experienced patients, including in head and neck lesions.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.8,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease: A National Cohort Study of the MarketScan Databases.","authors":"Julian A Cortes, Yvonne Nong, Kimberly Smart, Shaliz Aflatooni, Gabriela Palma, Nicole Johnsen, Andrea Ure, April W Armstrong","doi":"10.1007/s40257-026-01032-3","DOIUrl":"https://doi.org/10.1007/s40257-026-01032-3","url":null,"abstract":"","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.8,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Past, Present, and Future of Sodium Hypochlorite in Dermatology: A Scoping Review.","authors":"Christy H Chang, Maura Devine, Deborah Woo, Theresa Hopkins, Tiago Torres, Raj Chovatiya","doi":"10.1007/s40257-026-01024-3","DOIUrl":"https://doi.org/10.1007/s40257-026-01024-3","url":null,"abstract":"","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.8,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147715699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying the Most Relevant Eczema Area and Severity Index Thresholds from the Patient Perspective in Atopic Dermatitis Treatment.","authors":"Lawrence F Eichenfield, Peter A Lio, Alan D Irvine, Christian J Apfelbacher, Kenji Kabashima, Amy H Praestgaard, Zhixiao Wang, Mike Bastian","doi":"10.1007/s40257-026-01017-2","DOIUrl":"https://doi.org/10.1007/s40257-026-01017-2","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic inflammatory disease significantly impacting patients' quality of life (QoL). While multiple outcome measures exist, a critical gap remains in establishing treatment goals that meaningfully connect improvements in clinician-reported outcome measures (ClinROMs) with patient-reported outcome measures (PROMs).</p><p><strong>Objective: </strong>To determine the Eczema Area and Severity Index (EASI) threshold that best corresponds with clinically meaningful and optimal treatment responses in PROMs, linking ClinROMs and PROMs.</p><p><strong>Methods: </strong>LIBERTY AD CHRONOS, a randomized controlled trial, included adult patients treated with dupilumab 300 mg every 2 weeks plus topical corticosteroids. In this post-hoc analysis of the trial, repeated-measures regression analysis was used to quantify the relationship between EASI and improvements in PROMs.</p><p><strong>Results: </strong>Most clinically meaningful responses in PROMs were associated with 50-75% EASI improvement from baseline with the greatest impact on achieving clinically meaningful and optimal PROM responses when transitioning from EASI-50 to EASI-75 and minimal additional benefit when transitioning from EASI-75 to EASI-90 and EASI-90 to EASI-100. Two PROM composite end points, encompassing treatment responses in symptoms and QoL, confirmed these findings.</p><p><strong>Conclusions: </strong>This analysis bridges clinician-reported EASI with PROMs, demonstrating that EASI-75 aligns closely with clinically meaningful and optimal treatment responses from the patient perspective, providing a treatment goal that is both meaningful to patients and visually quantifiable for physicians in moderate-to-severe AD [Graphical abstract available online].</p><p><strong>Clinicaltrials: </strong></p><p><strong>Gov identifier: </strong>NCT02260986 (registered October 06, 2014).</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.8,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147715633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions.","authors":"Connie R Shi, Mihir K Patil, Grant J Riew, Badri Modi, Alina Markova, Edward W Cowen, Emily Baumrin","doi":"10.1007/s40257-026-01010-9","DOIUrl":"https://doi.org/10.1007/s40257-026-01010-9","url":null,"abstract":"<p><p>Cutaneous graft-versus-host disease (GVHD) is a frequent manifestation after allogeneic hematopoietic stem cell transplantation. This review synthesizes classification, pathophysiology, risk factors, and diagnostic frameworks for acute and chronic cutaneous GVHD. Acute cutaneous GVHD typically presents as a morbilliform eruption, with severe cases presenting with bullae and full-thickness desquamation. Chronic cutaneous GVHD presents in more protean ways, including both nonsclerotic and sclerotic phenotypes. We review current diagnostic criteria, staging, clinical and histopathologic features, and differential diagnoses of acute and chronic cutaneous GVHD. Additionally, we summarize management across the disease continuum, including skin-directed therapy, systemic therapy, and approved therapies for steroid-refractory GVHD such as ruxolitinib and remestemcel-L for acute GVHD and ibrutinib, ruxolitinib, belumosudil, and axatilimab for chronic GVHD. We also discuss emerging therapeutic strategies and areas of active investigation in GVHD therapeutics. However, despite therapeutic advances for chronic GVHD (cGVHD), nonresponse and relapse remain common. Early dermatologic involvement to diagnose, classify, and participate in multidisciplinary management is critical to improving outcomes for patients experiencing cutaneous GVHD. Biomarker-informed risk stratification and treatment selection, mechanistically informed combination regimens, and steroid-sparing first-line approaches for GVHD treatment are research priorities to enhance efficacy while minimizing toxicity.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.8,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?","authors":"S Morteza Seyed Jafari, Gemma Caro, Shari R Lipner, Matilde Iorizzo","doi":"10.1007/s40257-026-01021-6","DOIUrl":"https://doi.org/10.1007/s40257-026-01021-6","url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the treatment of type II diabetes and obesity. Since their introduction, studies continue to reveal their beneficial effects in a range of other conditions. However, hair loss associated with GLP-1RAs is still a controversial topic. This narrative review explores the current evidence linking GLP-1RAs to hair-related conditions because, while some studies have reported hair regrowth in patients with androgenetic alopecia and a decrease in inflammatory infiltrate in patients with cicatricial alopecia, many more have suggested association with telogen effluvium. Given the heterogeneity of current reports, careful clinical evaluation, monitoring weight trends, and assessing relevant laboratory parameters is recommended. Prospective, controlled studies, including immunohistochemical or molecular profiling of GLP-1 receptor expression in human hair follicles, are necessary to better clarify the potential role of GLP-1RAs in hair biology, to inform safe prescribing practices and to avoid discontinuation of a beneficial treatment.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.8,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dissecting Cellulitis of the Scalp: Current Insights and Therapeutic Advances.","authors":"Luca Valtellini, Gabriele Perego, Italo Francesco Aromolo, Chiara Moltrasio, Carlo Alberto Maronese, Angelo Valerio Marzano, Andrea Sechi, Gianluca Avallone","doi":"10.1007/s40257-026-01028-z","DOIUrl":"https://doi.org/10.1007/s40257-026-01028-z","url":null,"abstract":"<p><p>Dissecting cellulitis of the scalp is a rare, primary neutrophilic cicatricial alopecia that manifests with painful nodules, abscesses, and interconnected sinus tracts. It predominantly affects young adult men and frequently coexists with other follicular occlusion disorders, including hidradenitis suppurativa and acne conglobata. Clinical evaluation and trichoscopy are key elements of the diagnostic work-up, allowing detection of both early non-scarring inflammatory changes and features of chronic fibrotic disease. Although a wide array of therapeutic options has been explored, which range from oral antibiotics and retinoids to biologic agents, evidence-based guidelines remain lacking, and disease recurrence is common upon treatment cessation. Recent therapeutic advances have identified tumor necrosis factor-α, interleukin-17, and interleukin-23 inhibitors as promising options in recalcitrant cases. Adjunctive modalities such as laser-based therapies, surgical excision, and photodynamic protocols further expand the therapeutic paradigm, particularly for advanced disease. Increasing clinical and pathogenic evidence supports shared inflammatory pathways between dissecting cellulitis of the scalp and hidradenitis suppurativa, suggesting that these entities may represent anatomical variants within the same disease spectrum, driven by follicular occlusion and dysregulated immune responses. This evolving view harbors important implications for disease classification and management. The aim of this review is to provide an updated overview of the latest evidence on dissecting cellulitis of the scalp, encompassing its epidemiology, pathogenesis, clinical presentation, diagnostic algorithm, and therapeutic strategies. Additionally, we critically evaluate the conceptual framework for viewing dissecting cellulitis of the scalp and hidradenitis suppurativa as phenotypic variants of a unified inflammatory disorder and assess the current unmet need and future perspectives in translational research and disease management.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.8,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147626593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}